Modeling the effect of enzyme replacement therapy on life-threatening complications in patients with Fabry disease

• Váldodahkkit: V. I. Ignatyeva (Dahkki), S. V. Moiseev (Dahkki), N. M. Bulanov (Dahkki), E. A. Karovajkina (Dahkki), A S. Moiseev (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: IRBIS LLC, 2019-01-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Fabry disease (FD) is a severe lysosome storage disease caused by congenital deficiency of the enzyme α-galactosidase A and characterized by the risk of renal failure combined with cardiovascular and CNS complications. According to the currently available information, the early start of enzyme repla...